Showing 8361-8370 of 9426 results for "".
- FotoFinder Universe App Permits Image Access Via iPadhttps://practicaldermatology.com/news/20130215-fotofinder_universe_app_permits_image_access_via_ipad/2459614/Physicians can access before and after photos from an iPad for viewing, editing, and comparison, using FotoFinder's new Universe app for iPad 2, 3 and 4 and iPad mini. Used in conjunction with the company's mediscope photo documentation suite and Sate
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now avai
- Merz Aesthetics Appoints New VPhttps://practicaldermatology.com/news/20130206-merz_aesthetics_appoints_new_vp/2459620/Jim Hartman has been appointed Vice President of Merz Aesthetics, Inc. Business Unit, which includes Xeomin, Radiesse, and Belotero Balance. Prior to joining Merz, Hartman was the Vice President, Global Marketing & Business Development, at Obagi Medical Products, a provider of topical skincare treat
- La Roche-Posay Contributes to The Mollie Biggane Melanoma Foundationhttps://practicaldermatology.com/news/20130203-la_roche-posay_contributes_to_the_mollie_biggane_melanoma_foundation/2459621/As part of their continued efforts towards sun safety education and awareness, La Roche-Posay is partnering with Mollie's Fund for the second year in a row. To honor the life of Mollie Biggane – a college sophomore who tragically passed away from melanoma a
- La Roche-Posay Launches New Pore-Refining Moisturizerhttps://practicaldermatology.com/news/20130201-la_roche-posay_launches_new_pore-refining_moisturizer/2459623/La Roche-Posay's launched the Effaclar MAT Daily Mattifying + Pore-Refining Moisturizer, a formula that contains a unique combination of ingredients that neutralizes shine for lastingly matte, clear, and balanced skin with tightened pores, according to the company. The product is designed for patien
- AADA Applauds Proposed Legislation to Repeal Medicare's IPABhttps://practicaldermatology.com/news/20130130-aada_applauds_proposed_legislation_to_repeal_medicares_ipab/2459624/The American Academy of Dermatology Association (AADA) issued a statement applauding the introduction of the Protecting Seniors' Access to Medicare Act, legislation that would repeal the Independent Payment Advisory Board (IPAB) created by the 2010 Affordable Care Act. The AADA argues that the IPAB
- Provectus Launches Free Investor Relations Apphttps://practicaldermatology.com/news/20130124-provectus_launches_free_investor_relations_app/2459627/Provectus Pharmaceuticals, Inc. launched a free mobile shareholder investor relations application. The app offers immediate portable access to the company's latest news, financial information, presentations, and factsheet. The "Provectus IR" app is a
- Melanoma Rates Up as Overall US Cancer Incidence Fallshttps://practicaldermatology.com/news/20130123-melanoma_rates_up_as_overall_us_cancer_incidence_falls/2459629/While incidence rates are declining for most cancer sites, they are increasing among both men and women for melanoma of the skin and cancers of the liver, thyroid, and pancreas. Overall cancer incidence rates decreased slightly in males (by 0.6% per year) and were stable in females in the most recen
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130123-allergan_inc_to_acquire_map_pharmaceuticals_inc/2459632/Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 pe
- BOTOX Receives FDA Approval for Overactive Bladderhttps://practicaldermatology.com/news/20130121-botox_receives_fda_approval_for_overactive_bladder/2459633/The US FDA just approved BOTOX (onabotulinumtoxinA) from Allergan, Inc. for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults who have had an inadequate response to or are intol